Phase 1 N=3 Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal
Healthy
Primary: Efficacy of Tattoo Removal Using Topical Imiquimod 5% Cream — 4.3; 2.7 percentage of tattoo pigment removed
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=63 Safety and Efficacy of the Addition of Morphine Chloride to a Low Dose of Bupivacaine as Intradural Anaesthetic for the Removal Surgery of the Hemorrhoids
Surgical Remove of Hemorrhoids
Primary: Measurement of Time to Start the Anaesthetic Effect — 2.1; 1.6; 7.7; 4.7 minutes
Early Phase 1 N=20 Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
Phase 2 N=35 Pharmacokinetics, Efficacy and Tolerability of BIA 2-093
Epilepsy
Primary: Maximum Observed Plasma Drug Concentration (Cmax) Post-dose — 6921; 4820; 6382; 16183 ng/mL
Phase 2 N=10 Nitric Oxide, GeNO Nitrosyl Delivery System
Pulmonary Arterial Hypertension
Primary: Number of Participants With Side Effects and/or Adverse Events — 0 participants
Phase 2 N=12 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants
Phase 4 N=16 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
Kidney Diseases
Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day
Phase 2 N=38 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Adult Non-Hodgkin Lymphoma · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma
Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants
Phase 2 N=47 Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Detrusor Muscle Hyperactivity
Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11
Phase 2 N=279 An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to Week 18 — -0.01; -0.45; -0.61 Percent — p=<0.001
Phase 3 N=40 Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
Marfan Syndrome
Primary: Aortic Biophysical Properties - Pulse Wave Velocity — -1.15; -0.22 change in meters/second
Phase 2 N=30 DFA-02 in Patients Undergoing Colorectal Surgery
Surgical Site Infection
Primary: Number of Patients With Adverse Events, Laboratory, Physical Examination Changes — 23; 6; 5; 2 Participants
Phase 4 N=44 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection
Tendinopathy · Adrenal Insufficiency
Primary: Functional Improvement Measured According to Percentage Change in Constant Score — 99; 95 percentage of improvement Constant score
Phase 3 N=167 Implementing Evidence-Based Mental Health Practices in Primary Care
Alcohol Consumption
Primary: Reduction in Percentage of Heavy Drinking Days — 14.0; 11.0 percentage of heavy drinking days
N/A N=67 Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)
Stress Disorders, Post-Traumatic · Combat Disorders · Sleep Disorders
Primary: Change in Clinician Administered PTSD Scale for DSM-IV (CAPS) Recurrent Distressing Dreams Item — 3.1; 1.2 Scores on a Scale